Literature DB >> 6210262

Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.

G E Umbach, V Hug, G Spitzer, H Thames, B Drewinko.   

Abstract

The cytotoxicity of the investigational anticancer drugs fluoro-ara-AMP, homoharringtonine, and elliptinium on normal human granulocyte-macrophage colony-forming units in culture (GM-CFU) was investigated using a bilayer soft agar system. For each drug, the dose-dependent survival curve on a semilogarithmic plot formed a straight line. The D0 were: 0.51 microgram/ml (fluoro-ara-AMP), 0.004 microgram/ml (homoharringtonine) and 0.026 microgram/ml (elliptinium). The in vitro toxicity of drugs on bone marrow progenitor cells did not correlate with the relative myelosuppressive potency observed in vivo.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6210262     DOI： 10.1007/bf00175374

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  13 in total

1.  The antitumor effects and pharmacologic actions of harringtonine.

Authors: 
Journal:  Chin Med J (Engl)       Date:  1977-03       Impact factor: 2.628

2.  Colony stimulating factor augmentation in human placental conditioned medium.

Authors:  D S Verma; G Spitzer; M Beran; A R Zander; K B McCredie; K A Dicke
Journal:  Exp Hematol       Date:  1980-08       Impact factor: 3.084

3.  Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264--137) in advanced human cancers.

Authors:  P Juret; A Tanguy; A Girard; J Y Le Talaer; J S Abbatucci; N Dat-Xuong; J B Le Pecq; C Paoletti
Journal:  Eur J Cancer       Date:  1978-02       Impact factor: 9.162

4.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

5.  Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells.

Authors:  W Plunkett; S Chubb; L Alexander; J A Montgomery
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

6.  Patterns of cell survival following treatment with antitumor agents in vitro.

Authors:  B Drewinko; P R Roper; B Barlogie
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

7.  Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs.

Authors:  C H Park; P H Wiernik; F S Morrison; M Amare; K V Van Sloten; T R Maloney
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

8.  Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells.

Authors:  T L Jiang; R H Liu; S E Salmon
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

9.  Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.

Authors:  V I Avramis; W Plunkett
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

10.  Phase I trial of homoharringtonine.

Authors:  J A Neidhart; D C Young; D Derocher; E N Metz
Journal:  Cancer Treat Rep       Date:  1983-09
View more
  2 in total

1.  Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species.

Authors:  E Ortiz-Sánchez; T R Daniels; G Helguera; O Martinez-Maza; B Bonavida; M L Penichet
Journal:  Leukemia       Date:  2008-10-23       Impact factor: 11.528

2.  In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells.

Authors:  J A Ajani; G Spitzer; B Tomasovic; B Drewinko; V M Hug; K Dicke
Journal:  Br J Cancer       Date:  1986-10       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.